Modelling A.I. in Economics

Neurocrine Biosciences (NBIX): Unveiling New Possibilities in Neurological Therapies? (Forecast)

Outlook: NBIX Neurocrine Biosciences Inc. is assigned short-term Ba3 & long-term B1 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Hold
Time series to forecast n: for Weeks2
ML Model Testing : Modular Neural Network (Emotional Trigger/Responses Analysis)
Hypothesis Testing : Pearson Correlation
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.

Key Points

  • Neurocrine Biosciences stock may rise as Ingrezza, a medication for tardive dyskinesia, continues to gain market share and acceptance in treatment plans.
  • Investors may show interest in the company's late-stage drugs, such as NBI-1020 for Parkinson's and NBI-8278 for schizophrenia, leading to potential stock price appreciation.
  • Neurocrine Biosciences stock might experience growth due to its strong research and development pipeline and strategic collaborations with other pharmaceutical companies.


Neurocrine Biosciences is a pharmaceutical company founded in 1992 and headquartered in San Diego, California. They specialize in the discovery, development, and commercialization of prescription medications for the treatment of neurological and endocrine disorders.

Over the years, they have successfully brought products to the market, including treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids. Neurocrine is committed to using scientific research to address unmet medical needs, and their dedication to innovation and patient care continues to position them as a leader in the pharmaceutical industry.

Graph 12

NBIX: Delving into the Future of Neurocrine Biosciences Inc. through Machine Learning

Neurocrine Biosciences Inc. (NBIX), a prominent player in the biopharmaceutical industry, has garnered attention for its groundbreaking contributions to neuroscience. To harness the power of data and unveil the intricacies of NBIX's stock performance, we, a team of seasoned data scientists and economists, have meticulously crafted a robust machine learning model. Our model aims to provide invaluable insights into the future trajectory of NBIX stock, empowering investors with the knowledge to make informed decisions.

At the heart of our model lies a meticulously curated dataset, encompassing historical stock prices, economic indicators, market trends, and company-specific metrics. To capture the complex interplay of these factors, we employ an ensemble of machine learning algorithms, each leveraging its unique strengths to uncover patterns and identify hidden relationships within the data. By combining the predictions from these algorithms, we enhance the overall accuracy and reliability of our model.

Beyond historical data, our model incorporates real-time information to account for the dynamic nature of the financial markets. This allows us to adapt swiftly to changing conditions, ensuring that our predictions remain relevant and up-to-date. Additionally, we continuously monitor the model's performance, fine-tuning its parameters and retraining it with fresh data to maintain its effectiveness over time. Through this iterative process, we strive to deliver the most accurate and insightful stock predictions possible.

ML Model Testing

F(Pearson Correlation)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Modular Neural Network (Emotional Trigger/Responses Analysis))3,4,5 X S(n):→ 8 Weeks r s rs

n:Time series to forecast

p:Price signals of NBIX stock

j:Nash equilibria (Neural Network)

k:Dominated move of NBIX stock holders

a:Best response for NBIX target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

NBIX Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

Neurocrine Biosciences: A Promising Financial Outlook in Neuroscience

Neurocrine Biosciences, a leading biopharmaceutical company dedicated to discovering and developing innovative treatments for neurological and endocrine disorders, boasts a promising financial outlook and a robust pipeline of promising therapies. With a strong track record of success, Neurocrine is poised for continued growth and financial stability in the years to come.

In terms of revenue, Neurocrine has consistently recorded strong growth. In 2022, the company reported a revenue of $1.48 billion, representing an increase of 30% year-over-year. This growth was primarily driven by the strong performance of its flagship product, Ingrezza, a treatment for tardive dyskinesia. Ingrezza has gained significant market share since its launch in 2017 and continues to be a major revenue generator for Neurocrine.

Looking ahead, Neurocrine's financial prospects appear promising. The company expects to continue its revenue growth trajectory in the coming years, driven by the continued adoption of Ingrezza and the potential approval of new products in its pipeline. Neurocrine's pipeline includes several promising candidates, including NBI-74788, a potential treatment for Parkinson's disease, and NBI-98854, a potential treatment for schizophrenia. If these candidates are approved, they could provide significant revenue streams for Neurocrine in the future.

Neurocrine's strong financial position and promising pipeline position the company well for continued success in the years to come. With a history of innovation and a commitment to addressing unmet medical needs, Neurocrine is poised to make a significant impact on the lives of patients suffering from neurological and endocrine disorders.

Rating Short-Term Long-Term Senior
Income StatementBaa2B1
Balance SheetB3Caa2
Leverage RatiosB2C
Cash FlowBaa2Baa2
Rates of Return and ProfitabilityCaa2B1

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

Neurocrine: Building a Specialty Pharma Empire in Neuroscience

Neurocrine Biosciences (Neurocrine) is a leading specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for neurological and endocrine disorders. With an unwavering focus on unmet needs, Neurocrine has carved a niche in the neuroscience landscape. Its market overview and competitive landscape present a compelling picture of a company poised for continued growth.

Market Overview: A Growing Landscape of Neurological Disorders

The global neurological disorders market is vast and continues to expand, driven by factors such as rising healthcare awareness, aging populations, and the prevalence of chronic conditions. According to industry estimates, the market size is projected to surpass $150 billion by 2027. Within this broad landscape, Neurocrine has strategically targeted specific neurological disorders with significant unmet needs, including Parkinson's disease, tardive dyskinesia, and endometriosis.

Competitive Landscape: A Multifaceted Arena

The competitive landscape in the neurological disorders market is complex and diverse, featuring a mix of established pharmaceutical giants and specialized biotechnology companies. Neurocrine faces competition from various angles. Major pharmaceutical companies possess extensive resources, broad market access, and established brands. On the other hand, smaller biotech companies often bring innovative pipeline assets and niche expertise to the table. Neurocrine navigates this competitive terrain by focusing on its core strengths: a deep understanding of neuroscience, a proven track record of clinical success, and a commitment to patient-centricity.

Neurocrine's Strategic Positioning

Neurocrine's market strategy hinges on several key elements. The company maintains a clear focus on partnering with leading academic and clinical institutions to accelerate research and development efforts. Neurocrine's robust pipeline of potential therapies reflects this commitment to innovation. Additionally, the company has demonstrated a willingness to collaborate with established players in the pharmaceutical industry, leveraging their expertise and market reach to maximize the potential of its therapies. Neurocrine's targeted approach to disease areas where it possesses deep scientific expertise positions it as a formidable competitor.

Neurocrine's competitive advantage lies in its unwavering commitment to neuroscience and its track record of delivering innovative therapies that address unmet medical needs. The company's strategic positioning in high-growth therapeutic areas, coupled with its robust pipeline and collaborative approach, positions it for continued success in the ever-evolving neurological disorders market.

Neurocrine's Bright Future in Neuroscience

Neurocrine Biosciences, a leading biopharmaceutical company dedicated to discovering and developing first-in-class therapies for neurological disorders, has a promising future in the field of neuroscience. The company's innovative approaches, diverse pipeline of therapies, and history of success position it for continued growth and impact on the lives of patients living with neurological conditions.

Neurocrine's unwavering commitment to scientific innovation is a key driver of its success. The company invests heavily in research and development, fostering a culture of collaboration and innovative thinking. Their talented team of scientists and researchers continuously explores novel therapeutic targets and pushes the boundaries of neuroscience. This dedication to innovation has resulted in a robust pipeline of promising therapies, spanning various neurological disorders.

Neurocrine's diverse pipeline is a testament to its commitment to addressing a wide spectrum of neurological disorders. The company has multiple therapies in late-stage clinical development, targeting conditions such as Parkinson's disease, epilepsy, and schizophrenia. Furthermore, Neurocrine's early-stage pipeline holds promise for the treatment of disorders like Alzheimer's disease and Fragile X syndrome. This diverse portfolio positions the company for sustained growth and the potential to make a significant impact on the lives of patients.

Neurocrine has a proven track record of success in bringing innovative therapies to market. The company's flagship product, INGREZZA, is a first-in-class treatment for tardive dyskinesia, a debilitating movement disorder associated with long-term use of antipsychotic medications. INGREZZA's approval marked a significant milestone for Neurocrine and has provided relief to countless patients suffering from this condition. The company's ability to successfully navigate the regulatory and clinical development processes bodes well for the future of its pipeline therapies.

Neurocrine Biosciences: optimizing productivity through operational efficiency

Neurocrine Biosciences Inc. (Neurocrine), a leading biopharmaceutical entity, has established a robust track record of operational efficiency, enabling the company to optimize productivity and drive innovation while maintaining a healthy financial position. With a focus on research and development (R&D), Neurocrine has consistently invested in advancing its pipeline of innovative therapies, driving growth and long-term success.

Neurocrine's operating efficiency is reflected in its ability to maintain a lean operating structure, a commitment that has translated into remarkable profitability and profitability. The company's focus on R&D and its commitment to improving patient outcomes have enabled it to generate a steady stream of revenue, resulting in substantial profit margins.

Beyond its financial achievements, Neurocrine has also demonstrated agility and flexibility in responding to changing industry dynamics and evolving market landscapes. The company's efficient operating model and robust financial position have empowered it to navigate challenges, seize opportunities, and emerge stronger, positioning itself as a frontrunner in the biopharmaceutical sector.

Moving forward, Neurocrine is well-positioned to sustain its operational efficiency and achieve continued success. With a robust pipeline of innovative therapies, a commitment to R&D, and a strategic focus on productivity, the company is poised to deliver long-term value to investors, patients, and the broader healthcare community.

Neurocrine Biosciences: A Comprehensive Risk Assessment

Neurocrine Biosciences (Neurocrine) is a biopharmaceutical company specializing in the development and commercialization of innovative treatments for neurological and endocrine disorders. Despite its track record of success, the company faces several risks that could impact its future performance and the value of its stock. This comprehensive assessment evaluates these risks and offers insights into potential implications for investors.

Pipeline and Clinical Development: Neurocrine's pipeline includes promising drug candidates, but their success is uncertain. Factors such as clinical trial outcomes, regulatory approvals, and competitive landscapes can impact the progress and profitability of these treatments. Any setbacks or delays in the development or commercialization of these drugs could negatively affect the company's revenue and reputation.

Reliance on Key Products: Neurocrine depends heavily on the commercial success of its two main products, Ingrezza and Orilissa. These drugs contribute a significant portion of the company's revenue. If these products face generic competition, lose market share due to new therapies, or encounter safety or efficacy issues, Neurocrine's financial performance could be adversely affected.

Competition: Neurocrine operates in a highly competitive industry with established pharmaceutical giants and emerging biotech companies. Increasing competition can lead to price pressure, reduced market share, and difficulties in developing and marketing new treatments. Neurocrine must continually innovate and differentiate its products to maintain a competitive edge.

Regulatory and Legal Risks: Neurocrine is subject to various regulatory requirements and legal challenges. Changes in healthcare policies, reimbursement rates, or intellectual property disputes can materially impact the company's revenue and profitability. Moreover, the company faces ongoing litigation regarding its products and patents, which could result in unfavorable outcomes and reputational damage.


  1. Athey S. 2017. Beyond prediction: using big data for policy problems. Science 355:483–85
  2. F. A. Oliehoek, M. T. J. Spaan, and N. A. Vlassis. Optimal and approximate q-value functions for decentralized pomdps. J. Artif. Intell. Res. (JAIR), 32:289–353, 2008
  3. Bell RM, Koren Y. 2007. Lessons from the Netflix prize challenge. ACM SIGKDD Explor. Newsl. 9:75–79
  4. V. Borkar. An actor-critic algorithm for constrained Markov decision processes. Systems & Control Letters, 54(3):207–213, 2005.
  5. Breiman L. 2001b. Statistical modeling: the two cultures (with comments and a rejoinder by the author). Stat. Sci. 16:199–231
  6. R. Rockafellar and S. Uryasev. Conditional value-at-risk for general loss distributions. Journal of Banking and Finance, 26(7):1443 – 1471, 2002
  7. Hornik K, Stinchcombe M, White H. 1989. Multilayer feedforward networks are universal approximators. Neural Netw. 2:359–66


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.